Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$6.67 ▲ +0.04
(+0.60%)
MKT CAP: $638.0M • VOL: 1.47M
52W L $3 52W H $8
MYGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $824.5M | $837.6M | $753.2M |
| YoY Revenue Growth % | -1.6% | +11.2% | — |
| Gross Profit | $576.6M | $585.4M | — |
| Gross Margin % | 69.9% | 69.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$387.2M | -$123.5M | -$257.4M |
| Operating Margin % | -47.0% | -14.7% | -34.2% |
| Net Income (GAAP) | -$366.0M | -$127.0M | -$263.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.8M | -$8.7M | -$110.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $1.8M | -$8.7M | -$110.9M |
| FCF Margin % | 0.2% | -1.0% | -14.7% |
| Return on Invested Capital (ROIC %) | -45.0% | -15.3% | — |
| Cash & Short-Term Equivalents | $149.6M | $102.4M | — |
| Total Debt (Short + Long Term) | $119.9M | $39.6M | — |
| Total Stockholders' Equity | $368.0M | $701.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MYGN.